Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.

• DOI: 10.2310/7290.2012.00016
• Publication Date: 2013-01-01
• Authors: Albert J. Chang; Ravindra A. De Silva; Suzanne E. Lapi
• Keywords: Panitumumab; Biodistribution

The epidermal growth factor receptor (EGFR) is overexpressed in the majority of malignancies and has been associated with poor outcomes. Panitumumab, an anti-EGFR monoclonal antibody that binds to extracellular binding domain EGFR, increasingly used radiotherapy chemotherapy but toxicities. purpose this study was develop characterize a novel targeted imaging agent for EGFR using radiolabeled panitumumab. Flow cytometry studies were performed evaluate expression several cell lines. Desferrioxamine-Bz-NCS (DFO) conjugated panitumumab labeled (89)Zr. Cell uptake four For biodistribution micro-positron emission tomography/computed tomography (PET/CT), mouse xenograft models generated same PET performed, tumors select organs harvested studies. Panitumumab (89)Zr high radiochemical purity specific activity found be stable serum. demonstrated radiotracer cells correlated degree expression. MicroPET/CT intensity (89)Zr-panitumumab A431 HCT 116 comparison EGFR-negative tumors. Biodistribution confirmed results from EGFR-positive levels